Category Archives: Stem Cell Therapy

Introduction to Stem Cell Therapy
Dr. Michael Belich of Integrative Medical Clinics talks about Stem Cell Therapy basics. For more detailed information go to http://www.integrativemc.com.au.

By: Integrative Medical Clinics

Original post:
Introduction to Stem Cell Therapy - Video

Desiccated L4/5 disc five months after stem cell therapy by Dr Harry Adelson
A decorated war hero, Chris, discusses the stem cell injection into his L4/5 disc by Dr Harry Adelson http://www.docereclinics.com.

By: Harry Adelson, N.D.

See more here:
Desiccated L4/5 disc five months after stem cell therapy by Dr Harry Adelson - Video

New York, New York (PRWEB) April 03, 2014

Dr. Jeffrey Adler, New York podiatrist and Owner/Medical Director of Adler Footcare New York, will be interviewed by radio personality Laura Smith and taking live calls on New York talk show 77 WABC about the use of stem cells to treat chronic foot pain.

Adler Footcare New York uses live birth stem cells to help treat patients with chronic foot problems such as: Plantar fasciitis, Osteoarthritis, Achilles tendonitis and torn soft tissue. The stem cell treatment is proving to be much more effective than traditional treatments like physical therapy or orthotic therapy.

Stem cells have the ability to replicate themselves or change into the cell type that is needed to repair damaged tissue. The therapy works by directly introducing live stem cells into the affected area causing pain. Its approved by the FDA and consistently reviewed by medical professionals to remove the potential of any communicable diseases.

Dr. Adler often travels to other states to share his knowledge with other doctors in his profession. His latest research on stem cell therapy has gained much interest among his peers in the medical industry.

When compared to traditional treatments, stem therapy is proving to be more successful and longer lasting, Dr. Adler said. We are seeing patients heal much quicker and return to their normal activities much sooner.

To learn more about stem cell replacement therapy or to schedule a consultation with a New York podiatrist at Adler Footcare, call (212) 704-4310 or visit http://www.mynycpodiatrist.com.

About Adler Footcare New York Dr. Jeffrey L. Adler, Medical/Surgical Director and owner of Adler Footcare New York has been practicing podiatric medicine since 1979 and has performed thousands of foot and ankle surgeries. Dr. Adler is board certified in Podiatric Surgery and Primary Podiatric Medicine by the American Board of Multiple Specialties in Podiatry. Dr. Adler is also a Professor of Minimally Invasive Foot Surgery for the Academy of Ambulatory Foot and Ankle Surgeons. As one of only several in the country who perform minimally invasive podiatric surgery, Dr. Adlers patients enjoy significantly reduced recovery times.

Originally posted here:
New York Podiatrist Dr. Jeffrey Adler to Be Interviewed April 5 on NewsTalkRadio 77 WABC About the Use of Stem Cell ...

Dallas, TX (PRWEB) April 03, 2014

Translational Biosciences, a subsidiary of Medistem Panama, has received the green light for a phase I/II clinical trial using human umbilical cord-derived mesenchymal stem cells (UC-MSC) for multiple sclerosis from the Comit Nacional de Biotica de la Investigacin (CNEI) Institutional Review Board (IRB) in Panama.

According to the US National Multiple Sclerosis Society, in Multiple Sclerosis (MS), an abnormal immune-mediated T cell response attacks the myelin coating around nerve fibers in the central nervous system, as well as the nerve fibers themselves. This causes nerve impulses to slow or even halt, thus producing symptoms of MS that include fatigue; bladder and bowel problems; vision problems; and difficulty walking. The Cleveland Clinic reports that MS affects more than 350,000 people in the United States and 2.5 million worldwide.

Mesenchymal stem cells harvested from donated human umbilical cords after normal, healthy births possess anti-inflammatory and immune modulatory properties that may relieve MS symptoms. Because these cells are immune privileged, the recipients immune system does not reject them. These properties make UC-MSC interesting candidates for the treatment of multiple sclerosis and other autoimmune disorders.

Each patient will receive seven intravenous injections of UC-MSC over the course of 10 days. They will be assessed at 3 months and 12 months primarily for safety and secondarily for indications of efficacy.

The stem cell technology being utilized in this trial was developed by Neil Riordan, PhD, founder of Medistem Panama. The stem cells will be harvested and processed at Medistem Panamas 8000 sq. ft. ISO-9001 certified laboratory in the prestigious City of Knowledge. They will be administered at the Stem Cell Institute in Panama City, Panama.

From his research laboratory in Dallas, Texas, Dr. Riordan commented, Umbilical cord tissue provides an abundant, non-controversial supply of immune modulating mesenchymal stem cells. Preclinical and clinical research has demonstrated the anti-inflammatory and immune modulating effects of these cells. We look forward to the safety and efficacy data that will be generated by this clinical trial; the first in the western hemisphere testing the effects of umbilical cord mesenchymal stem cells on patients with multiple sclerosis.

The Principle Investigator is Jorge Paz-Rodriguez, MD. Dr. Paz-Rodriguez also serves as the Medical Director at the Stem Cell Institute.

For detailed information about this clinical trial visit http://www.clinicaltrials.gov . If you are a multiple sclerosis patient between the ages of 18 and 55, you may qualify for this trial. Please email trials (at) translationalbiosciences (dot) com for more information about how to apply.

About Translational Biosciences

View post:
Umbilical Cord Stem Cell Therapy Clinical Trial for Multiple Sclerosis Gets Green Light

Dr Antonia Park, according to the Professional Regulatory Commission, is not authorized to practice medicine in the Philippines. She faces charges of estafa and reckless imprudence resulting in homicide.

MANILA, Philippines The alternative medicine doctor who took in former president Gloria Macapagal-Arroyo in 2012 for possible stem cell therapy is not licensed to practice in the Philippines.

On Tuesday, April 1, Antonia Park of the Green & Young Health & Wellness Center admitted to Rappler in a phone interview she is not a registered physician in the Philippines because "I'm not from here." She is instead a registered medical practitioner in London and Korea.

"Thats why its a wellness center. If dito ako [registered], maglalagay na lang ako ng medical center," she said, referring to her center located in Tagaytay City. (That's why it's a wellness center. If I am registered here, I might as well put up a medical center.)

A document from the Professional Regulatory Commission (PRC) dated Aug 12, 2013 showed Park is not in the database of physicians which contains the names of those duly authorized to practice medicine in the Philippines.

Certification Antonia Carandang Park

Park and some of her clinic staff are facing charges of estafa and reckless imprudence resulting in homicide. The charges were filed last year by businessman Bernard Tan with the National Bureau of Investigation (NBI) after his 23-year-old daughter Kate died.

Kate, an Ateneo student who graduated with honors in March 2013, died 4 months later on July 4, due to a tumor that blocked the entry of blood to her heart, secondary to Hodgkin's Lymphoma. The disease is an uncommon but curable cancer of the lymphatic system.

High-profile patient

Continued here:
Arroyo's alternative medicine doctor unlicensed

Stem Cell Therapy - 2
2 .

By: tscmru

Originally posted here:
Stem Cell Therapy - 2 - Video

Scientists at The University of Nottingham have developed a new substance which could simplify the manufacture of cell therapy in the pioneering world of regenerative medicine.

Cell therapy is an exciting and rapidly developing area of medicine in which stem cells have the potential to repair human tissue and maintain organ function in chronic disease and age-related illnesses. But a major problem with translating current successful research into actual products and treatments is how to mass-produce such a complex living material.

There are two distinct phases in the production of stem cell products; proliferation (making enough cells to form large tissue) and differentiation (turning the basic stem cells into functional cells). The material environment required for these two phases are different and up to now a single substance that does both jobs has not been available.

Now a multi-disciplinary team of researchers at Nottingham has created a new stem cell micro-environment which they have found has allowed both the self-renewal of cells and then their evolution into cardiomyocyte (heart) cells. The material is a hydrogel containing two polymers -- an alginate-rich environment which allows proliferation of cells with a simple chemical switch to render the environment collagen-rich when the cell population is large enough. This change triggers the next stage of cell growth when cells develop a specific purpose.

Professor of Advanced Drug Delivery and Tissue Engineering, Kevin Shakesheff, said:

"Our new combination of hydrogels is a first. It allows dense tissue structures to be produced from human pluripotent stem cells (HPSC) in a single step process never achieved before. The discovery has important implications for the future of manufacturing in regenerative medicine. This field of healthcare is a major priority for the UK and we are seeing increasing investment in future manufacturing processes to ensure we are ready to deliver real treatments to patients when HPSC products and treatments go to trial and become standard."

The research, "Combined hydrogels that switch human pluripotent stem cells from self-renewal to differentiation" is published in the Proceedings of the National Academy of Sciences (PNAS).

Story Source:

The above story is based on materials provided by University of Nottingham. Note: Materials may be edited for content and length.

See the original post:
Major breakthrough in stem cell manufacturing technology